Sign in
WithdrawnPhase 2

Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity

Key facts

Who runs it
University of Minnesota
Where
Minneapolis, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
17 Oct 2023
Expected to end
Aug 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Qsymia and lifestyle management therapy
  • Placebo and lifestyle management therapy
Record updated
26 October 2023
Why it stopped
The project was not funded

Who can take part

Age
16 years to 22 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 37 criteriaShow less

Who can take part

  • Age 16 to less than 22 years at screening
  • BMI >/= 25 to < 30 kg/m\^2
  • Family history of obesity defined as one biological parent with severe obesity (BMI >/= 35) and/or two biological parents with obesity (BMI >/= 30)
  • Age 16 or 17 years old must also have an obesity-related complication/co-morbidity defined as elevated blood pressure (>/= 130 and/or >/= 80 milligrams of mercury [mmHg]) or current use of anti-hypertensive medication, dyslipidemia (triglycerides >/= 150 milligrams/deciliter (mg/dL) and/or HDL cholesterol < 40 mg/dL or current use of cholesterol-lowering medication, diagnosis of obstructive sleep apnea

Who cannot take part

  • Current or recent (< 6 months prior to enrollment) use of anti-obesity medication(s) and other weight-altering medication(s) (e.g.,, atypical antipsychotics, attention-deficit hyperactivity disorder [ADHD] stimulant)
  • Previous bariatric surgery
  • Current or recent (< 6 months prior to enrollment) use of medication(s) to treat insulin resistance
  • Recent initiation (< 3 months prior to enrollment) of anti-hypertensive or lipid medication(s)
  • Current or recent (< 14 days) use of monoamine oxidase inhibitor
  • History of treatment with growth hormone
  • Diabetes (1 or 2)
  • History of glaucoma
  • Known hypersensitivity to sympathomimetic amines
  • Eating disorder symptoms within 6 months and/r any past medical diagnosis of eating disorder
  • Major psychiatric disorder
  • History of suicide attempt
  • History of seizures
  • Uncontrolled hypertension
  • History of structural heart defect
  • History of clinically significant arrhythmia
  • History of cholelithiasis
  • History of nephrolithiasis
  • Untreated thyroid disorder
  • Alanine transaminase (ALT ) or Aspartate transaminase (AST) >/= 2.5 the upper limit of normal
  • Bicarbonate < 18 micromoles per liter (mmol/L)
  • Creatinine 1.2 mg/dL
  • Creatinine clearance of < 50 microliters per minute [mL/min] (Schwartz formula)
  • Tanner stage 1-4
  • Patient Health Questionnaire (PHQ) score of >/= 15
  • Unstable clinically-diagnosed depression
  • Suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the last month
  • Current pregnancy or breastfeeding
  • Plans to become pregnant
  • If sexually active, refusal to use 2 forms of birth control
  • Tobacco use
  • Diagnosed monogenic obesity
  • Hyperthyroidism

Where in United States

  • University of MinnesotaMinneapolis, United States

About the trial

What the trial wants to find out

This study will test the use of phentermine and topiramate compared with placebo in helping adolescents who are at high risk for developing obesity to lose weight

The 2 groups in the trial

  • Medication armTreatment being tested

    Individuals randomized to this group will be offered lifestyle-based weight gain prevention counseling. Participants will initiate treatment at 3.75 mg/23 mg orally once in the morning for 14 days, which will then be increased to 7.5 mg/46 mg orally once daily in the morning for the remainder of the trial. Participants who are unable to tolerate the dosing regimen will be maintained at the maximally tolerated dose. To further safeguard the risk/benefit balance we will utilize a down-titration protocol for participants who experience a reduction in BMI below a threshold of 20 kg/m2. In this case, participants will be reduced to the lowest-dose level (3.75 mg/23 mg) for 12 weeks. If the BMI remains below 20 kg/m2 at the lowest dose after 12 weeks, active treatment will be fully withdrawn. Participants at the end of the study will be down-titrated gradually with instructions to take the medication every other day for 7 days before stopping treatment altogether.

    Treatment: Qsymia and lifestyle management therapy

  • Placebo armPlacebo, for comparison

    Individuals randomized to this group will be offered lifestyle-based weight gain prevention counseling. Participants will initiate treatment with a placebo (to keep the blind) and be asked to up-titrate the placebo dose after the first 14 days and then maintain the placebo dose for the remainder of the study. Individuals who are unable to tolerate the dosing regimen will have a down-titration protocol (to maintain the blind) as described in the medication arm. Likewise, we will employ a down-titration protocol for participants who experience a reduction in BMI below a threshold of 20 kg/m2. In this case, participants would be reduced to the lowest dose level of placebo for 12 weeks. If the BMI remains below 20 kg/m2 after 12 weeks, placebo treatment will be fully withdrawn. Individuals in the placebo arm will also have a placebo-based down-titration with instructions to take the placebo every other day for 7 days before stopping treatment altogether, to maintain the blind.

    Treatment: Placebo and lifestyle management therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
26 October 2023